Pemetrexed in advanced non-small cell lung cancer

被引：20

作者：

Gridelli, Cesare ^{[1
]}

Maione, Paolo ^{[1
]}

Rossi, Antonio ^{[1
]}

Bareschino, Maria Anna ^{[1
]}

Schettino, Clorinda ^{[1
]}

Sacco, Paola Claudia ^{[1
]}

Zeppa, Rosario ^{[1
]}

机构：

[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy

来源：

EXPERT OPINION ON DRUG SAFETY | 2011年 / 10卷 / 02期

关键词：

chemotherapy; NSCLC; pemetrexed; safety; PHASE-III TRIAL; CISPLATIN PLUS GEMCITABINE; 1ST-LINE CHEMOTHERAPY; CARBOPLATIN; BEVACIZUMAB; PACLITAXEL; ANTIFOLATE; GEFITINIB; DOCETAXEL; LY231514;

D O I：

10.1517/14740338.2011.553281

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: For patients with advanced NSCLC, treatment outcomes are still disappointing and the search for new active and safe drugs is warranted. The chemotherapeutic agent pemetrexed has produced, in the last years, an innovation of therapeutic algorithms of this disease, and this review is aimed at describing the role of pemetrexed in the treatment of NSCLC. Areas covered: In the present review, we discuss the mechanism of action of pemetrexed, its safety profile and the main clinical data on pemetrexed in NSCLC treatment. The reader will gain information on pemetrexed efficacy in the first-line, second-line and maintenance treatment of advanced NSCLC. Moreover, the histotype-based approach to NSCLC treatment, which is important for the selection of patients to be treated with pemetrexed, is clarified. Expert opinion: The recent introduction of pemetrexed in the first-line and maintenance treatment of advanced non-squamous NSCLC represents, in our opinion, a significant step forward in the treatment of this disease in the last 3 years. Furthermore, cisplatin plus pemetrexed has a more favorable safety profile as compared with those of pre-existing cisplatin-based regimens.

引用

页码：311 / 317

页数：7

共 27 条

[1] Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].

Breathnach, OS ;

Freidlin, B ;

Conley, B ;

Green, MR ;

Johnson, DH ;

Gandara, DR ;

O'Connell, M ;

Shepherd, FA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742

[2] Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase [J].

Ceppi, Paolo ;

Volante, Marco ;

Saviozzi, Silvia ;

Rapa, Ida ;

Novello, Silvia ;

Cambieri, Alberto ;

Lo Iacono, Marco ;

Cappia, Susanna ;

Papotti, Mauro ;

Scagliotti, Giorgio V. .

CANCER, 2006, 107 (07) :1589-1596

[3] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [J].

Ciuleanu, Tudor ;

Brodowicz, Thomas ;

Zielinski, Christoph ;

Kim, Joo Hang ;

Krzakowski, Maciej ;

Laack, Eckart ;

Wu, Yi-Long ;

Bover, Isabel ;

Begbie, Stephen ;

Tzekova, Valentina ;

Cucevic, Branka ;

Pereira, Jose Rodrigues ;

Yang, Sung Hyun ;

Madhavan, Jayaprakash ;

Sugarman, Katherine P. ;

Peterson, Patrick ;

John, William J. ;

Krejcy, Kurt ;

Belani, Chandra P. .

LANCET, 2009, 374 (9699) :1432-1440

[4] Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database [J].

Govindan, Ramaswamy ;

Page, Nathan ;

Morgensztern, Daniel ;

Read, William ;

Tierney, Ryan ;

Vlahiotis, Anna ;

Spitznagel, Edward L. ;

Piccirillo, Jay .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4539-4544

[5] Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line? [J].

Gridelli, Cesare ;

Maione, Paolo ;

Rossi, Antonio ;

Ferrara, Marianna Luciana ;

Bareschino, Maria Anna ;

Schettino, Clorinda ;

Sacco, Paola Claudia ;

Ciardiello, Fortunato .

ONCOLOGIST, 2009, 14 (02) :137-147

[6] Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer [J].

Gronberg, Bjorn H. ;

Bremnes, Roy M. ;

Flotten, Oystein ;

Amundsen, Tore ;

Brunsvig, Paal Fr. ;

Hjelde, Harald H. ;

Kaasa, Stein ;

von Plessen, Christian ;

Stornes, Froydis ;

Tollali, Terje ;

Wammer, Finn ;

Aasebo, Ulf ;

Sundstrom, Stein .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3217-3224

[7] Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: A review of the literature [J].

Grossi, Francesco ;

Aita, Marianna ;

Follador, Alessandro ;

Defferrari, Carlotta ;

Brianti, Annalisa ;

Sinaccio, Graziella ;

Belvedere, Ornella .

ONCOLOGIST, 2007, 12 (04) :451-464

[8] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[9] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. [J].

Maemondo, Makoto ;

Inoue, Akira ;

Kobayashi, Kunihiko ;

Sugawara, Shunichi ;

Oizumi, Satoshi ;

Isobe, Hiroshi ;

Gemma, Akihiko ;

Harada, Masao ;

Yoshizawa, Hirohisa ;

Kinoshita, Ichiro ;

Fujita, Yuka ;

Okinaga, Shoji ;

Hirano, Haruto ;

Yoshimori, Kozo ;

Harada, Toshiyuki ;

Ogura, Takashi ;

Ando, Masahiro ;

Miyazawa, Hitoshi ;

Tanaka, Tomoaki ;

Saijo, Yasuo ;

Hagiwara, Koichi ;

Morita, Satoshi ;

Nukiwa, Toshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25) :2380-2388

[10]

MAIONE P, 2010, EXPERT OPIN PHARMACO

← 1 2 3 →